European shares gain as Genmab jumps, bond yields retreat

European stocks

Article originally published by Reuters. Hargreaves Lansdown is not responsible for its content or accuracy and may not share the author's views. News and research are not personal recommendations to deal. All investments can fall in value so you could get back less than you invest.

European shares rose to near one-week highs on Tuesday, as Genmab led gains in healthcare stocks, while euro zone bond yields took a breather after rallying on fiscal and inflation concerns.

The pan-European ​STOXX ⁠600 index was up 0.8% to 638.41 points by ⁠0727 GMT, poised for a third straight session of gains.

Genmab climbed 7.6% to the top of ​STOXX 600 after the Danish biotech firm and US drugmaker AbbVie's blood cancer drug combination cut risk ​of progression or death in ⁠a late-stage study.

The broader healthcare sector was up 1.6%.

Attention now ⁠turns to euro zone retail sales data and the UK S&P ‌Global PMI survey due later ​in the day, which could offer clues about the region's consumer ⁠spending and Britain's economic activity.

The euro hovered near a ‌17-month low, weighed down by political uncertainty after ​Spanish ‌Prime Minister Pedro Sanchez called a snap election on Monday.

Meanwhile, ‌the French government is seeking to ⁠enact ⁠an unpopular 2027 budget to lower its deficit, sparking a rout in bonds.

Still, euro zone bond yields eased, having touched multi-decade highs last week. [GVD/EUR]

Among other stocks, Italy's ​Technoprobe gained 2.3% after J.P.Morgan initiated coverage on the ⁠stock with ‌an "overweight" rating.

(Reporting by Sudeshna Ghoshal ​in ‌Bengaluru; Editing by Mrigank Dhaniwala)

Copyright (2026) Thomson Reuters.

This article was from Reuters and was legally licensed through the DiveMarketplace by Industry Dive. Please direct all licensing questions to legal@industrydive.com.

Weekly Newsletter
Sign up for Editor's choice. Get more investing insight like this in our weekly newsletter – Editor's choice.